AUPH

Aurinia Pharmaceuticals Inc

AUPH.US auriniapharma.com
16.11
-0.14 (-0.86%)
USD · NASDAQ
52-week range
10.34
19.25
Trading at 65% of the 52-week range
Market Cap
2.16B
P/E Ratio
7.07
Forward P/E
11.30
Book Value
4.63
Div. Yield
N/A
% Institutions
60.53%
% Insiders
6.63%

1 Year

+31.8%

3 Year

+65.7%

10 Year

+649.3%
Description

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Company Information

Company Name
Aurinia Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: CA05156V1022
CIK: 0001600620
CUSIP: 05156V102
Currency: USD
Full Time Employees: 128
Phone: 250 744 2487
Fiscal Year End: December
IPO Date: Jan 26, 1999
Description:

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Address:

#140, 14315 ? 118 Avenue, Edmonton, AB, Canada, T5L 4S6

People

Directors & Officers

Name Title Year Born
Mr. Kevin C. Tang Chairman & CEO 1967
Mr. Stephen P. Robertson Chief Legal Officer, Corporate Secretary & Chief Compliance Officer 1982
Mr. Peter S. Greenleaf M.B.A. Consultant 1970
Mr. Michael S. Hearne CPA Chief Financial Officer 1963
Mr. Ryan Cole Chief Operating Officer 1987
Mr. Thomas Wei Chief Scientific Officer 1976
Mr. Stewart M. Kroll Chief Development Officer 1959

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 27, 2026 Kevin Tang N/A Purchase 516.44K $13.99 $7.22M
Aug 05, 2025 Kevin Tang N/A Purchase 200.00K $11.68 $2.34M
Aug 04, 2025 Kevin Tang N/A Purchase 100.00K $11.34 $1.13M
Aug 01, 2025 Kevin Tang N/A Purchase 1.00M $10.12 $10.12M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
TANG CAPITAL MANAGEMENT LLC 12.23M Mar 31, 2026 9.19% $9.20 7.94%
BlackRock Inc 7.85M Mar 31, 2026 5.90% $0.00 -1.04%
NEA Management Company, LLC 3.97M Mar 31, 2026 2.98% $3.34 0.00%
Two Sigma Investments LLC 3.43M Mar 31, 2026 2.58% $0.04 74.69%
Arrowstreet Capital Limited Partnership 3.28M Mar 31, 2026 2.47% $0.03 -3.04%
State Street Corp 2.53M Mar 31, 2026 1.90% $0.00 1.00%
Morgan Stanley - Brokerage Accounts 2.23M Mar 31, 2026 1.68% $0.00 0.71%
Marshall Wace Asset Management Ltd 1.87M Mar 31, 2026 1.41% $0.03 19.03%
Renaissance Technologies Corp 1.66M Mar 31, 2026 1.25% $0.04 4.63%
Geode Capital Management, LLC 1.54M Mar 31, 2026 1.15% $0.00 1.87%
The Goldman Sachs Group Inc 1.43M Mar 31, 2026 1.08% $0.00 42.45%
D. E. Shaw & Co LP 1.41M Jun 30, 2026 1.06% $0.01 -10.46%
Vanguard Portfolio Management, LLC 1.26M Mar 31, 2026 0.94% $0.00 0.00%
Jacobs Levy Equity Management, Inc. 1.10M Mar 31, 2026 0.82% $0.07 -3.69%
Jupiter Asset Management Limited 1.09M Jun 30, 2026 0.82% $0.09 36.23%
LSV Asset Management 1.08M Jun 30, 2026 0.81% $0.03 3.84%
Nomura Holdings Inc 978.60K Jun 30, 2026 0.74% $0.02 1.00%
Man Group PLC 951.41K Mar 31, 2026 0.72% $0.03 11.58%
AQR Capital Management LLC 948.81K Mar 31, 2026 0.71% $0.01 97.12%
Qube Research & Technologies 930.63K Mar 31, 2026 0.70% $0.02 6.44%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Russell 2000 ETF 3.03M 2.28% ▼ 0.57% Aug 31, 2026
2 Fidelity Small Cap Index 1.29M 0.97% ▲ 9.01% Jun 30, 2026
3 iShares Russell 2000 Growth ETF 1.12M 0.84% ▲ 0.00% Aug 31, 2026
4 GS Glb Sm Cp CORE Eq Base Inc USD Snap 910.17K 0.68% ▲ 52.07% Jun 30, 2026
5 iShares Biotechnology ETF 853.51K 0.64% ▲ 0.80% Aug 31, 2026
6 Russell 2000 Equity Index Fund B 773.72K 0.58% ▲ 2.34% Jun 30, 2026
7 Russell 2000 Index Non-Lendable Fund 773.72K 0.58% ▲ 2.34% Jun 30, 2026
8 State St Russell Sm/Mid Cp® Indx SL Cl I 722.20K 0.54% ▲ 0.00% Jul 31, 2026
9 Vanguard Russell 2000 ETF 669.17K 0.50% ▼ 2.53% Jul 31, 2026
10 Goldman Sachs US Tax-Managed Eq Instl 541.44K 0.41% ▲ 0.00% Jun 30, 2026

Financial Highlights

Market Cap: $2.16B
EBITDA: $179.83M
P/E Ratio: $7.07
PEG Ratio: $0.00
Book Value: $4.63
Earnings/Share: $2.30
Profit Margin: 100.84%
Operating Margin: 55.69%
ROA (TTM): 15.49%
ROE (TTM): 66.12%
Revenue (TTM): $311.51M
Revenue/Share (TTM): $2.37
Earnings Growth (YOY): 75.50%
Revenue Growth (YOY): 18.90%

Valuation Metrics

Enterprise Value: $1.78B
Trailing P/E: 7.07
Forward P/E: 11.30

Shares Statistics

Shares Outstanding: 133.05M
Shares Float: 129.10M
% Insiders: 6.63%
% Institutions: 60.53%
Short % Float: 7.98%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$283.06M
Cost of Goods Sold
adjust
$-32.67M
Gross Profit
subtotal
$250.39M
SG&A
adjust
$-98.59M
R&D
adjust
$-32.51M
Other Operating Expense
adjust
$-14.39M
Operating Income
subtotal
$104.91M
Other / Non-Operating Items
adjust
$182.29M
Net Income
subtotal
$287.20M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AUPH.US!